Glucagon antibody

Catalog No. ABIN7181328

The Mouse Monoclonal anti-Glucagon antibody has been validated for IHC and ELISA. It is suitable to detect Glucagon in samples from Human.

Quick Overview for Glucagon antibody (ABIN7181328)

Target: Glucagon (GCG)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Glucagon antibody is un-conjugated

Application: Immunohistochemistry (IHC), ELISA

Product Details anti-Glucagon Antibody

Cross-Reactivity: Human

Purification: Affinity purified

Immunogen: Synthesized peptide derived from human Glucagon

Isotype: IgG2b kappa

Application Details

Application Notes: Recommended dilution: IHC:1:20-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for Glucagon

Target: Glucagon (GCG)

Alternative Name: GCG

Background:

Background: Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.

Edoardo C. Aromataris, J. Physiol., Jun 2006, 573: 611 - 625.
Xiao C. Li, Hypertension, Mar 2006, 47: 580 - 585.
Kirstan A. Vessey, Invest. Ophthalmol. Vis. Sci., Nov 2005, 46: 3922 - 3931.
Xiaosong Ma, Mol. Endocrinol., Jan 2005, 19: 198 - 212.

Aliases: Glicentin, Glicentin-related polypeptide, Oxyntomodulin, Glucagon-like peptide 1(GLP-1), Glucagon-like peptide 1(7-37)

UniProt: P01275

Pathways: Positive Regulation of Peptide Hormone Secretion, Peptide Hormone Metabolism, cAMP Metabolic Process, Regulation of Carbohydrate Metabolic Process, Feeding Behaviour, Negative Regulation of intrinsic apoptotic Signaling